All Articles

With massive data center orders but cautious guidance, the industrial giant's upcoming conference talks are a key test of investor confidence.

With revolutionary tech and a volatile stock, PureCycle's year-end update is a critical test of its operational progress and financial promises.

With a history of massive contract wins and M&A success, Bob Genter's appointment signals Peraton is doubling down on aggressive growth and operational might.

Lay's emotional 'Last Harvest' was America's top Super Bowl ad, but a new report reveals a huge generational divide, with Gen Z crowning a different winner.

National Storage Affiliates Trust declared a steady dividend, but a look at its financial performance reveals a complex picture for investors.

ECI Group and Marcus Partners acquire a 280-unit Atlanta complex, planning major renovations to capitalize on a recovering apartment market near key job hubs.

As Perimeter preps its year-end results, investors are watching if its aggressive diversification can overcome operational hurdles and justify its new shape.

A new $7B annual funding plan saves Ontario's colleges and universities but raises tuition and shifts student aid from grants to loans, sparking debt fears.

A new 'longevity center' in Naperville signals a growing trend in proactive health, but what does this mean for the Chicago wellness landscape?

The retail REIT reports record-breaking leasing and strong profits for 2025, while executing a strategic portfolio overhaul and setting a confident tone for 2026.

Twilio reports a landmark year of GAAP profitability and robust growth, signaling a strategic pivot to AI as it guides for a billion in 2026 cash flow.

Despite Q4 headwinds, the auto supplier's massive EV wins and deep focus on China fuel an ambitious 2026 forecast for double-digit profitability.

As Liberty Latin America preps its 2025 results, investors watch to see if strong subscriber growth and cost-cutting can sustain momentum in a competitive market.

Aethlon Medical advances its Hemopurifier for oncology and Long COVID, but a shrinking cash reserve and rising quarterly loss test its lean science strategy.

Investors and patients await Puma Bio's Q4 results, focusing on NERLYNX sales performance and crucial updates on its promising alisertib cancer pipeline.

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.

A jury verdict against Olin Corporation in a contract dispute with Shintech will cost the chemical giant $185 million and raises industry-wide questions.

The industrial giant posted strong 2025 results and a cautious 2026 outlook, banking on its execution strategy and key acquisitions in high-growth markets.

The Midwest bank saw record earnings and shareholder returns in 2025, but a rise in nonperforming loans adds a layer of complexity to its growth story.

Forward Industries' radical crypto pivot is a wild ride. Staking revenue is up 4x, but a market downturn triggered a staggering half-billion-dollar loss.